文献速递流行病学与生物统计真实世界研究与卫生经济

肿瘤学临床预测模型的批判性综述:SEER 研究是否严谨?

A critical review of clinical prediction models in oncology: is this SEERious research?
PubMed 文献 · J Clin Epidemiol · 2026-10-15

该研究系统综述了利用 SEER 数据库开发的临床预测模型研究,检索 2023 年 1 月 1 日至 8 月 10 日 MEDLINE 文献,纳入 436 项研究。结果发现 94% 第一作者来自中国机构,报告指南依从性低(13%),仅 6% 中国研究说明拟应用临床场景,87% 未讨论 SEER 适用性;十年间此类研究超 4000 项,年产出从 2016 年 37 项增至 2023 年超 700 项。

要点

  • SEER 预测模型研究激增,但多数缺乏明确研究理由、目标人群和临床用途。
  • 报告指南依从性仅 13%,研究方案提及率 3%,方法学质量堪忧。
  • 读者应审慎对待 SEER 预测模型研究,期刊与审稿人需加强把关。

核心结论

  • 仅拥有数据不足以证明模型开发的合理性,多数 SEER 预测模型缺乏清晰报告的理由、目标人群和临床目的。
  • 许多研究科学价值有限,呈现为仅提升研究者简历的公式化研究特征。

研究设计与样本

  • 系统综述,检索 MEDLINE via PubMed 2023 年 1 月 1 日至 8 月 10 日发表的临床预测模型开发研究。
  • 纳入标准为使用 SEER 数据库中两个及以上预测因子开发临床预测模型的研究,共纳入 436 项 eligible 研究。

主要发现

  • 436 项研究中 94%(n=412)第一作者隶属中国机构,3%(n=14)来自美国。
  • 模型主要针对肺癌(11%)和乳腺癌(10%),87% 聚焦预后;Cox 回归占 59%,列线图占 77%。
  • 报告指南依从性低(13%),研究方案极少提及(3%);32% 模型将患者种族作为预测因子。
  • 中国 affiliated 研究中仅 6% 报告拟应用临床场景,3% 说明拟使用国家;87% 研究未讨论 SEER 适用性;22% 中国研究使用中国数据做外部验证。
  • 十年间 MEDLINE 索引的 SEER 预测模型研究超 4000 项,年产出从 2016 年 37 项增至 2023 年超 700 项。

临床怎么用

  • 临床读者应审慎对待基于 SEER 的预测模型研究,直至有证据表明其方法学严谨且具临床相关性。
  • 期刊、同行审稿人和数据保管方应共同确保利用广泛可用数据集的研究达到高标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) cancer registry covers almost half the United States population. Clinical prediction models developed using the SEER cancer registry have rapidly grown in number. We sought to characterise and examine the extent to which this body of work reflects formulaic research practices, reflected by a lack of clear objectives, substandard methods and practices with limited scientific value. STUDY DESIGN AND SETTING: We conducted a systematic review of clinical prediction model development studies using the SEER data. MEDLINE via PubMed was searched for studies published between January 1 and August 10, 2023. Studies were included if they developed a clinical prediction model using two or more predictors from the SEER database. Data extraction covered study context, intended use, predictor characteristics, reporting guideline adherence, external validation practices, and the rationale provided for using SEER. RESULTS: Of 436 eligible studies, 94% (n=412) had first authors affiliated with institutions in China, while 3% (n=14) were from the United States. Developed models mostly targeted lung (11%) and breast (10%) cancers, and most focussed on prognosis (87%). Cox regression was the predominant modelling approach (59%), and nomograms were the most common presentation format (77%). Reporting guideline adherence was low (13%), and study protocols were rarely mentioned (3%). Nearly one third of models included patients' race as a predictor (32%). Of the China-affiliated studies, only 6% reported an intended clinical setting, and 3% specified the intended country of use. Discussion of the suitability of SEER was absent in 87% of included studies. Among China-affiliated studies, 22% carried out external validation using data from China. Over a ten-year period, expanding our search strategy identified more than 4,000 SEER-based prediction model studies indexed in MEDLINE, with annual output growing from 37 in 2016 to over 700 in 2023. CONCLUSIONS: Access to data alone does not justify model development. Most prediction models developed using SEER lack a clearly reported rationale, defined target population, an intended clinical purpose, and fail to address whether the models produced with the SEER data are appropriate for populations outside the United States. Readers should treat SEER-based prediction model studies with appropriate scepticism until evidence of rigorous methodology and clinical relevance is demonstrated. Many studies have limited scientific value and exhibit hallmarks of formulaic research created solely to boost researcher's resumé. Journals, peer reviewers, and data custodians all have a responsibility to ensure high research standards for studies exploiting widely available datasets, as the growing volume of such output places editorial and peer review systems under increasing strain.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Tsegaye B, Ma J, Fryc J, et al. A critical review of clinical prediction models in oncology: is this SEERious research? J Clin Epidemiol. 2026. PMID: 42880677. doi:10.1016/j.jclinepi.2026.112566

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。